• Sectors we work in banner(2)

    Quick Reads

The ongoing fight against fakes

When counterfeit goods are mentioned, initial thoughts may be of luxury items such as handbags copied in a far cheaper and more accessible form. Hidden behind such goods is the harm done to rights holders, who have invested time and money developing and producing a product, and the organised crime and downstream harm caused by such counterfeit items. However, other products are also counterfeited and the impact to the consumer can be more immediate and dangerous – electrical goods and pharmaceuticals are two categories that are also frequently copied.

EUROPOL recently coordinated the fourth edition of Operation SHIELD, a global effort to tackle fake pharmaceuticals.  The operation saw 1,284 individuals charged and took fake medicines worth EUR 64 million off EU markets.

The sale of fake pharmaceuticals, and illegal trafficking of pharmaceuticals, continues to be a growing issue and is a significant public health problem.

The Internet remains an enticing outlet for suppliers of counterfeit goods and social media is a current popular forum for selling counterfeit and illegally sold medicines. Of key importance is educating users of social media, particularly younger generations, on the significant safety risks associated with sourcing pharmaceuticals outside the legitimate supply chain. As consumers, it is key that we question what the item is and where it has come from.

Brand owners should seek to protect and enforce their trade mark rights to help curb the proliferation of counterfeit products worldwide and protect consumers. 

The EUROPOL press release makes for impressive reading but the fight against counterfeiters is ongoing. Vigilance by consumers and brand owners, and protection of important intellectual property, are key.

 

Medicines are often counterfeited in underground laboratories without any regulation or safety measures in place. Counterfeit products created under such circumstances do not produce the desired effect; in the best case scenario the patient remains untreated, however such products can cause serious health issues or be potentially lethal.

Our thinking

  • CTBUH Annual Conference: Mastering ESG Challenges and the Launch of the Global In-House Counsel Assembly

    Kerry Stares

    Events

  • IBA Annual Conference 2024

    Charlotte Ford

    Events

  • International Arbitration Conference 2024 conference

    Thomas R. Snider

    Events

  • Regime change: The beginning of the end of the remittance basis

    Dominic Lawrance

    Insights

  • Oasis and the Often Overlooked Benefit of Dynamic Pricing

    Nick White

    Quick Reads

  • Q&A: What evidence can establish boundaries?

    Chandni Pandya

    Insights

  • Estates Gazette, New Civil Engineer and BE News quote David Savage on the Grenfell Phase 2 Inquiry report

    David Savage

    In the Press

  • Property Week quotes James Souter on a legal case relating to Annington Properties and the Leasehold and Freehold Reform Act

    James Souter

    In the Press

  • Thomas Moran and Ruth Morris write for Prime Resi on the future of London's prime property market

    Thomas Moran

    In the Press

  • Budgeting for change: what should Landed Estates be doing before the Budget?

    Sarah Wray

    Quick Reads

  • FCA Consultations on prospectus regime

    Jodie Dennis

    Insights

  • The Telegraph quotes Dominic Lawrance on anticipated tax changes and the impact on non-doms

    Dominic Lawrance

    In the Press

  • “I object!” The use of non-objection clauses and confidentiality provisions in the context of Development Consent Order applications

    Rachael Davidson

    Insights

  • Darren Bailey writes for City AM on the NFL’s decision to allow private equity investment

    Darren Bailey

    In the Press

  • Relocation to Italy: Italian Lump Sum Tax Regime

    Nicola Saccardo

    Insights

  • App Fraud - where are we now?

    Caroline Greenwell

    Insights

  • Caroline Greenwell, Bella Henry and Simon Heatley write for Law 360 on APP Fraud – where are we now?

    Caroline Greenwell

    In the Press

  • Mark White writes for The Carer on the evolving landscape of healthcare real estate

    Mark White

    In the Press

  • Charles Russell Speechlys advises EMMA Systems on strategic reorganisation and investment

    Alex Reid

    News

  • Adviser.ca quotes Robert Reymond and Jonathan Rothwell on the abolition of the UK non-dom regime and options available for existing non-doms

    Robert Reymond

    In the Press

Back to top